Evelio Sosa, MD
Psychiatry · Miami, FLNPI 1114055761
Payments from drug & device makers
What this record shows
Merck accounts for 94.2% of it on its own, with 2 other manufacturers making up the rest.
Across 13 payments — averaging $76.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$939
- Lundbeck LLC$34
- Otsuka America Pharmaceutical, Inc.$24
Across 72 payments — averaging $96,432 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$4.6M
- Axsome Therapeutics, Inc.$2M
- Acadia Pharmaceuticals Inc$172K
- E.r. Squibb & Sons, L.L.C.$121K
What the payments were for
- Travel & lodging$46947%
- Food & beverage$52853%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 10 | $939 |
| Lundbeck LLC | 2 | $34 |
| Otsuka America Pharmaceutical, Inc. | 1 | $24 |
How this compares
$996 in reported general payments places this provider in the 60th percentile of 2,059 psychiatry providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Quetiapine Fumarate | 1,441 | $6,192 |
| Buspirone Hcl | 945 | $5,756 |
| Clonazepam | 745 | $4,354 |
| Bupropion XlBupropion Hcl | 370 | $3,764 |
| Trazodone Hcl | 1,056 | $3,688 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 78 | $2,756 |
| Escitalopram Oxalate | 741 | $2,659 |
| Mirtazapine | 417 | $2,421 |
| Clozapine | 38 | $1,778 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 200 | $1,643 |
| Sertraline Hcl | 433 | $1,623 |
| Memantine Hcl ErMemantine Hcl | 20 | $1,540 |
| Aripiprazole | 101 | $1,390 |
| Alprazolam | 649 | $1,339 |
| Temazepam | 361 | $1,318 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Miami
- Kenny PerezMiami$453K
- Erik CabreraMiami$357K
- Miguel FloresMiami$176K
- Pedro RodriguezMiami$96K
- John NewcomerMiami$96K
- Patricia JunqueraMiami$80K
- Marc AgroninMiami$66K
- Andrew CutlerLakewood Ranch$5.7M
- Richard JacksonBoca Raton$3.6M
- Ilan MelnickCoral Gables$2.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.